Merck scores priority review Keytruda in squamous NSCLC; Synthetic Genomics spinout SGI-DNA gets new CEO

→ The FDA has accepted — and given priority review — to Merck’s supplemental biologics license application for its cancer immunotherapy Keytruda. The pharma giant is hoping the drug will be approved in a new indication: metastatic squamous non-small cell lung cancer. This is Merck’s anti-PD-1 therapy, in combination with carboplatin-paclitaxel or nab-paclitaxel as a first-line treatment. Merck $MRK has been pouring billions of dollars into its Keytruda pipeline, and the investment has paid off handsomely with a blockbuster franchise and a collection of more than 750 trials — an explosion of clinical research. For this latest indication, the FDA gave Merck a PDUFA of October 30, 2018.

→ SGI-DNA, a La Jolla spinout from J. Craig Venter’s company Synthetic Genomics, has named a new leader to the helm. Todd Nelson, the former CEO of San Francisco Bay Area’s DiscoverX Corporation, is joining SGI-DNA as CEO. Nelson has led several companies through phases of growth, including eBioscience, which was acquired by Affymetrix (now Thermo Fisher); and MP Biomedicals, which was acquired by Valeant Fine Chemicals. The news of Nelson’s appointment comes just weeks after SGI-DNA’s former president Nathan Wood announced he was leaving the company for a new gig at Swift Biosciences.

The best place to read Endpoints News? In your inbox.

Comprehensive daily news report for those who discover, develop, and market drugs. Join 37,600+ biopharma pros who read Endpoints News by email every day.

Free Subscription

Biotech Investment Analyst
SV Health Investors Boston, MA
Director, Program Management
Contrafect Corporation New York, NY
Director, Translational Sciences
Cadent Therapeutics Cambridge, MA

Visit Endpoints Careers ->